We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma

Source: Pharmacy Times articles LBL-034 could be best in class in treating individuals with multiple myeloma. Read More

Recent Publications

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia

Heliyon. 2024 Oct 22;10(21):e39698. doi: 10.1016/j.heliyon.2024.e39698. eCollection 2024 Nov 15....

A systematic literature review on clonal evolution events preceding relapse in multiple myeloma

Crit Rev Oncol Hematol. 2024 Nov 14:104560. doi: 10.1016/j.critrevonc.2024.104560. Online ahead of...

Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis

Ann Hematol. 2024 Nov 8. doi: 10.1007/s00277-024-06078-z. Online ahead of print. ABSTRACT To...

A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma

Ther Adv Hematol. 2024 Nov 13;15:20406207241292517. doi: 10.1177/20406207241292517. eCollection...

Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review

Imaging Sci Dent. 2024 Sep;54(3):221-231. doi: 10.5624/isd.20240032. Epub 2024 Jul 17. ABSTRACT...

Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review

Crit Rev Oncol Hematol. 2024 Oct 3:104529. doi: 10.1016/j.critrevonc.2024.104529. Online ahead of...

Email

info@myeloma360.com